Oragenics (NYSEAMERICAN:OGEN – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.58) earnings per share (EPS) for the quarter, FiscalAI reports.
Oragenics Trading Down 50.9%
Shares of OGEN stock traded down $0.18 during trading hours on Friday, reaching $0.17. 4,398,427 shares of the company’s stock were exchanged, compared to its average volume of 338,618. Oragenics has a 1 year low of $0.17 and a 1 year high of $1.15. The stock’s fifty day moving average price is $0.44 and its two-hundred day moving average price is $0.58. The stock has a market cap of $775,720.00, a PE ratio of -0.01 and a beta of 1.28.
About Oragenics
Oragenics, Inc. is a biotechnology company focused on developing intranasal medicines for neurological disorders. Its approach is designed to deliver drug candidates through the nasal passage directly to the brain, with the goal of addressing conditions for which conventional drug-delivery methods may be limited. The company’s lead product candidate is ONP-002, an intranasal therapy being developed for the treatment of concussion and traumatic brain injury. Oragenics has also pursued additional preclinical programs targeting neurological and neurodegenerative diseases, although the development status and scope of these programs may change as the company advances its pipeline.
See Also
- Five stocks we like better than Oragenics
- Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
